Phase 3 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a consent form before entering the study
• People aged between 18 and 78 years old
• People who have been diagnosed with active multiple myeloma, as defined by international myeloma guidelines
• People who have waited at least 7 days since their last dose of combination or single-agent chemotherapy before starting the stem cell collection preparation process
• People whom the treating doctor considers suitable for an autologous stem cell transplant (a transplant using the patient's own stem cells)
• People whose multiple myeloma is in a first or second complete response (disease not detectable) or partial response (disease reduced but not gone) at the time of joining
• People with a good general level of physical functioning (able to carry out normal daily activities with little or no restriction)
• People whose heart, liver, kidneys, and other organs are working adequately at the time of screening
• Female participants who are not able to become pregnant, or who have a negative pregnancy test at screening and again within 72 hours before starting treatment; women who could become pregnant and male participants whose partners could become pregnant must agree to use highly effective contraception during the study and for 90 days after the last study treatment

Who may not be able to join:

• People who have previously had an autologous or donor stem cell transplant
• People who have previously had an unsuccessful stem cell collection attempt
• People who have taken certain medications (including dexamethasone, thalidomide, lenalidomide, pomalidomide, bortezomib, carfilzomib, certain growth factors, daratumumab, or other related drugs) within specific waiting periods before the study starts (confirm exact timeframes with trial site)
• People who have received more than 6 cycles of thalidomide or lenalidomide in total across their treatment history
• People who have received more than 8 cycles of chemotherapy combinations containing alkylating agents (a type of chemotherapy drug)
• People who have received more than 6 cycles of melphalan (a specific chemotherapy drug)
• People who have previously been treated with radioimmunotherapy (treatment using radioactive substances attached to antibodies)
• People who have previously been treated with venetoclax (a targeted cancer drug)
• People who plan to receive maintenance therapy (ongoing treatment to keep the disease in check) within 60 days after the transplant
• People who have received a live vaccine within 30 days before starting the stem cell collection preparation (non-live seasonal flu vaccines are permitted)
• People with known active cancer spread to the brain or the lining around the brain
• People with a known allergy to motixafortide, G-CSF (a growth factor used in stem cell collection), or other drugs used in the study
• People with an active or uncontrolled infection that requires medical treatment
• People with another known cancer that is growing or currently requires treatment
• People currently taking part in another clinical trial or who have received an experimental treatment within 4 weeks of starting this study
• People with blood oxygen levels below 92% when breathing normal room air
• People with a personal or family history of certain heart rhythm conditions (Long QT Syndrome or Torsade de Pointes)
• People with a history of unexplained fainting, fainting due to an uncorrected heart problem, or a family history of sudden cardiac death
• People who have had a heart attack, heart surgery, stroke, artery stenting, angioplasty, or hospitalisation for heart failure within the past 3 months, or who have significant chest pain or heart failure symptoms
• People whose heart tracing (ECG) at screening shows certain abnormal electrical readings (confirm specifics with trial site)
• People with certain types of heart conduction (electrical signal) problems, unless they have an implanted pacemaker or defibrillator
• People with known psychiatric conditions or substance use disorders that would make it difficult to participate fully in the trial
• People who are pregnant, breastfeeding, or planning to become pregnant, or women who could become pregnant and are unwilling to use two methods of contraception or a highly effective method throughout the trial and for 90 days after the last dose
• People known to have HIV, or active Hepatitis B or Hepatitis C infections
• People with any other condition, treatment history, or laboratory result that the treating doctor believes would make participation unsafe or interfere with the trial results

Important: Always verify eligibility with the trial site directly before applying.